Editorial Board
Peiying Yang
Department of Palliative, Rehabilitation and Integrative Medicine, Division of Cancer Medicine · United States
Editorial leadership for Journal of Developments in Mass Spectrometry
Research interests
- Cancer Biology
- Cancer Cells
- Signaling Pathways
Biography
Education & Training
Degree-Granting Education
- 1997 University of Maine, Orono, ME, USA, PHD, Nutritional Biochemistry
- 1990 Beijing University of Traditional Chinese Medicine, Beijing, CHN, MS, Pharmacy
- 1987 Beijing University of Traditional Chinese Medicine, Beijing, CHN, BS, Traditional Chinese Medicine
Postgraduate Training
- 1998-2003 Postdoctoral Fellowship, The University of Texas MD Anderson Cancer Center, Houston
Experience & Service
Academic Appointments:
- Assistant Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2013
- Assistant Professor, Department of Behavioral Science, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2008
- Assistant Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2008
- Instructor, Department of Department of Experimental Therapeutics, UT MD Anderson Cancer Center, Houston, TX, 2003 - 2006
Other Appointments/Responsibilities
- Senior Project Manager of Pharmaceutical Development Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2008
- Director of R&D and Formulation, International Nutraceutical Corporation, Ogden, UT, 1997 - 1998
- Institutional Committee Activities
- Member, Multidisciplinary Research Advisory Committee, 2013 - Present
Consultantships
- Applied Photon Medical Technologies Inc, Houston, Texas, USA, 2013 – 2015
Honors & Awards
- 2004 Prostate Cancer Research Program Award
- 1995 Gordon E. Ramsdell Scholarship
- 1995 Merna Monroe Kappa Omicron Nu Scholarship
Selected publications
- Human Biofield Therapy Modulates Tumor Microenvironment and Cancer Stemness in Mouse Lung Carcinoma 2020 cited 19×
- Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma 2023 cited 12×
- Weight Loss and/or Sulindac Mitigate Obesity-associated Transcriptome, Microbiome, and Protumor Effects in a Murine Model of Colon Cancer 2022 cited 9×
- Are Published Cancer Care Trial Protocols With Traditional Chinese Medicine Interventions Concordant With SPIRIT-TCM Extension 2018? A Scoping Review on Published Trial Protocols Between 2019 and 2022 2024 cited 1×
- Figure S1-S5 from Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma 2023
- Data from Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma Recent 2025
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JDMS for your work?
This journal is guided by Peiying Yang (Department of Palliative, Rehabilitation and Integrative Medicine, Division of Cancer Medicine) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.